Related Experiment Video
Updated: Apr 5, 2026
Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro
Published on: February 15, 2022
Vascular Smooth Muscle as a Target for Novel Therapeutics
Karen E Porter1, Kirsten Riches
1Division of Cardiovascular & Diabetes Research, Leeds Institute of Cardiovascular & Metabolic Medicine (LICAMM) and Multidisciplinary Cardiovascular Research Centre (MCRC), University of Leeds, Leeds, LS2 9JT, UK, k.e.porter@leeds.ac.uk.
Abstract:
Cardiovascular disease is the principal cause of death in patients with type 2 diabetes (T2DM). Exposure of the vasculature to metabolic disturbances leaves a persistent imprint on vascular walls, and specifically on smooth muscle cells (SMC) that favours their dysfunction and potentially underlies macrovascular complications of T2DM. Current diabetes therapies and continued development of newer treatments has led to the ability to achieve more efficient glycaemic control. There is also some evidence to suggest that some of these treatments may exert favourable pleiotropic effects, some of which may be at the level of SMC. However, emerging interest in epigenetic markers as determinants of vascular disease, and a putative link with diabetes, opens the possibility for new avenues to develop robust and specific new therapies. These will likely need to target cell-specific epigenetic changes such as effectors of DNA histone modifications that promote or inhibit gene transcription, and/or microRNAs capable of regulating entire cellular pathways through target gene repression. The growing epidemic of T2DM worldwide, and its attendant cardiovascular mortality, dictates a need for novel therapies and personalised approaches to ameliorate vascular complications in this vulnerable population.
Insights
Cardiovascular disease remains a major threat for type 2 diabetes patients. Novel therapies targeting epigenetic changes in vascular smooth muscle cells offer new hope for preventing diabetes-related heart complications.
Area of Science:
- Vascular biology
- Endocrinology
- Epigenetics
Background:
- Cardiovascular disease (CVD) is the leading cause of mortality in type 2 diabetes mellitus (T2DM).
- Metabolic disturbances in T2DM cause persistent vascular changes, particularly in smooth muscle cells (SMCs), leading to dysfunction and macrovascular complications.
- While current therapies improve glycemic control, their pleiotropic effects on SMCs are under investigation.
Purpose of the Study:
- To explore the role of epigenetic modifications in T2DM-associated vascular complications.
- To identify potential therapeutic targets within SMCs for novel diabetes treatments.
- To highlight the need for personalized approaches to manage vascular health in T2DM.
Main Methods:
- Review of current literature on T2DM, CVD, SMC biology, and epigenetics.
- Analysis of emerging evidence on epigenetic markers (DNA histone modifications, microRNAs) in vascular disease.
- Exploration of potential therapeutic strategies targeting cell-specific epigenetic changes.
Main Results:
- Metabolic disturbances in T2DM induce lasting epigenetic alterations in vascular SMCs.
- Epigenetic mechanisms, including histone modifications and microRNAs, are implicated in SMC dysfunction and vascular disease.
- Existing and novel diabetes treatments may have beneficial effects at the SMC level.
Conclusions:
- Epigenetic modifications represent a promising frontier for developing targeted therapies against T2DM-related CVD.
- Targeting cell-specific epigenetic changes in SMCs could offer novel treatment strategies.
- Addressing the growing epidemic of T2DM requires innovative and personalized approaches to mitigate vascular complications.
Related Concept Videos
01:23Antihypertensive Drugs: Vasodilators
01:25Smooth Muscle Contraction
The onset of contraction is triggered by an increase in calcium ions within the sarcoplasm, similar to the process in striated muscle. However, smooth muscles have a relatively smaller reservoir of the sarcoplasmic...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
01:24Regulation of Angiogenesis and Blood Supply